MMJ International Holdings Corp.
MMJ International Holdings is dedicated to advancing the science of medical cannabis through patient clinical research and the operation of healthcare businesses. The company aims to develop FDA-approved cannabis medicines to improve patients' lives, especially those with unmet medical needs. They focus on discovering, developing, manufacturing, and commercializing medicines for underserved populations, reaching beyond boundaries to develop new cannabis-based FDA-approved medicines, and making a difference in patients' lives with genomics and information technology.
Industries
Nr. of Employees
small (1-50)
MMJ International Holdings Corp.
Products
Cannabinoid-derived drug candidates for multiple sclerosis and Huntington’s disease
Plant-derived cannabinoid pharmaceutical candidates formulated as APIs and liquid-filled soft gelatin capsules, under development for treatment of neurodegenerative diseases with planned clinical evaluation.
MMJ-002
A proprietary THC and CBD drug formulation awarded Orphan Drug Designation by the FDA for the treatment of Huntington’s Disease.
MMJ 001
An oral drug product in liquid-filled soft gelatin capsule form derived from marijuana plant containing THC and CBD as a natural whole plant extract, developed for treating multiple sclerosis (MS) and Huntington’s disease (HD).
lead product candidate
A liquid formulation of highly purified CBD/THC being investigated for severe neurological disorders, including forms of spasticity and chorea due to multiple sclerosis and Huntington’s disease.
Cannabinoid-derived drug candidates for multiple sclerosis and Huntington’s disease
Plant-derived cannabinoid pharmaceutical candidates formulated as APIs and liquid-filled soft gelatin capsules, under development for treatment of neurodegenerative diseases with planned clinical evaluation.
MMJ-002
A proprietary THC and CBD drug formulation awarded Orphan Drug Designation by the FDA for the treatment of Huntington’s Disease.
MMJ 001
An oral drug product in liquid-filled soft gelatin capsule form derived from marijuana plant containing THC and CBD as a natural whole plant extract, developed for treating multiple sclerosis (MS) and Huntington’s disease (HD).
lead product candidate
A liquid formulation of highly purified CBD/THC being investigated for severe neurological disorders, including forms of spasticity and chorea due to multiple sclerosis and Huntington’s disease.
Services
Preparation and submission of regulatory applications (pre-IND, IND, Orphan Drug) and support for Phase II clinical study planning and execution.
Development of APIs and finished dosage forms under cGMP, including liquid encapsulation into soft gelatin capsules and scale-up with specialty pharmaceutical manufacturers.
Analytical testing capabilities in a federally authorized lab for Schedule I substances to support quality control and regulatory compliance.
Assistance with DEA Schedule I registration processes, cultivation licensing for research supply, and alignment with FDA regulatory expectations.
Application of genomics and information-technology capabilities to support research data analysis and clinical research workflows.
Preparation and submission of regulatory applications (pre-IND, IND, Orphan Drug) and support for Phase II clinical study planning and execution.
Development of APIs and finished dosage forms under cGMP, including liquid encapsulation into soft gelatin capsules and scale-up with specialty pharmaceutical manufacturers.
Analytical testing capabilities in a federally authorized lab for Schedule I substances to support quality control and regulatory compliance.
Assistance with DEA Schedule I registration processes, cultivation licensing for research supply, and alignment with FDA regulatory expectations.
Application of genomics and information-technology capabilities to support research data analysis and clinical research workflows.
Expertise Areas
- Clinical trial management for cannabinoid medicines
- Regulatory compliance with FDA and DEA for controlled substances
- Pharmaceutical formulation development (softgel encapsulation)
- cGMP manufacturing for botanical-derived APIs and finished dosage forms
Key Technologies
- Cannabinoid-based pharmaceutical formulations
- Liquid-filled soft gelatin capsule formulation
- cGMP manufacturing processes
- Stability testing and shelf-life studies
News & Updates
MMJ BioPharma Labs has received DEA Schedule 1 registration, enabling them to produce and handle Schedule 1 substances for research and development.
The DEA is considering granting MMJ BioPharma cultivation license to supply pharmaceutical research and development.
MMJ has filed an FDA application to start clinical trials for a cannabis-based medicine for multiple sclerosis.
MMJ has filed an orphan drug application with the FDA for its cannabinoid drug MMJ-002 to treat Huntington’s Disease.
MMJ received FDA Orphan Drug Designation for its cannabinoid drug MMJ-002 for Huntington’s Disease.
MMJ BioPharma Labs has received DEA Schedule 1 registration, enabling them to produce and handle Schedule 1 substances for research and development.
The DEA is considering granting MMJ BioPharma cultivation license to supply pharmaceutical research and development.
MMJ has filed an FDA application to start clinical trials for a cannabis-based medicine for multiple sclerosis.
MMJ has filed an orphan drug application with the FDA for its cannabinoid drug MMJ-002 to treat Huntington’s Disease.
MMJ received FDA Orphan Drug Designation for its cannabinoid drug MMJ-002 for Huntington’s Disease.